神経内分泌がん(Neuroendocrine Carcinoma):治療薬開発パイプライン動向2014

◆英語タイトル:Neuroendocrine Carcinoma-Pipeline Insights, 2014
◆商品コード:DELVE41017464
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2014年版(※最新版はお問い合わせください)
◆ページ数:60以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(約3営業日所要)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、世界における神経内分泌がん(Neuroendocrine Carcinoma)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の製品リスト等をお届けしています。また、神経内分泌がん(Neuroendocrine Carcinoma)治療薬開発に取り組んでいる企業情報も提供しています。(※本レポートはご注文を頂いてから、最新データに更新して納品しているため、正確なページ数を明記しておりません。)

・神経内分泌がん(Neuroendocrine Carcinoma)の概要

・神経内分泌がん(Neuroendocrine Carcinoma)のパイプライン製品概要

・企業別開発中の治療薬

・後期治験段階の製品(Filed & Phase III):比較分析

・中期治験段階の製品(Phase II):比較分析

・初期治験段階の製品(Phase I & IND):比較分析

・前臨床段階の製品:比較分析

・薬剤候補のプロファイル

・神経内分泌がん(Neuroendocrine Carcinoma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 投与経路別
  - 分子の種類別

・開発が中止された製品リスト

・開発休止中の製品リスト

・神経内分泌がん(Neuroendocrine Carcinoma)治療薬開発に取り組んでいる企業リスト

・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s,“ Neuroendocrine Carcinoma-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Neuroendocrine Carcinoma. This report provides information on the therapeutic development based on the Neuroendocrine Carcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.


Scope
• The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Carcinoma
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Neuroendocrine Carcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Neuroendocrine Carcinoma and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
• Complete Pipeline intelligence and complete understanding over therapeutics development for Neuroendocrine Carcinoma
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Neuroendocrine Carcinoma pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions


【レポートの目次】

Table of Contents
• Neuroendocrine Carcinoma Overview
• Neuroendocrine Carcinoma Pipeline Therapeutics
• Neuroendocrine Carcinoma Therapeutics under Development by Companies
• Neuroendocrine Carcinoma Late Stage Products (Filed and Phase III)
– Comparative Analysis
• Neuroendocrine Carcinoma Mid Clinical Stage Products (Phase II)
– Comparative Analysis
• Neuroendocrine Carcinoma Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
• Neuroendocrine Carcinoma Discovery and Pre-Clinical Stage Products
– Comparative Analysis
• Drug Candidate Profiles
• Neuroendocrine Carcinoma – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
• Neuroendocrine Carcinoma – Discontinued Products
• Neuroendocrine Carcinoma – Dormant Products
• Companies Involved in Therapeutics Development for Neuroendocrine Carcinoma
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Neuroendocrine Carcinoma, 2014
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
• Drug Candidates Profiles
• Neuroendocrine Carcinoma Assessment by Monotherapy Products
• Neuroendocrine Carcinoma Assessment by Combination Products
• Neuroendocrine Carcinoma Assessment by Route of Administration
• Neuroendocrine Carcinoma Assessment by Stage and Route of Administration
• Neuroendocrine Carcinoma Assessment by Molecule Type
• Neuroendocrine Carcinoma Assessment by Stage and Molecule Type
• Neuroendocrine Carcinoma Therapeutics – Discontinued Products
• Neuroendocrine Carcinoma Therapeutics – Dormant Products
• Products under Development by Companies, 2014


List of Figures
• Number of Products under Development for Neuroendocrine Carcinoma, 2014
• Late Clinical Stage Products (Filed and Phase III), 2014
• Mid Clinical Stage Products (Phase II), 2014
• Early Clinical Stage Products (Phase I and IND Filed), 2014
• Discovery and Pre-Clinical Stage Products, 2014
• Neuroendocrine Carcinoma Assessment by Monotherapy Products
• Neuroendocrine Carcinoma Assessment by Combination Products
• Neuroendocrine Carcinoma Assessment by Route of Administration
• Neuroendocrine Carcinoma Assessment by Stage and Route of Administration
• Neuroendocrine Carcinoma Assessment by Molecule Type
• Neuroendocrine Carcinoma Assessment by Stage and Molecule Type


【レポートのキーワード】

神経内分泌がん(Neuroendocrine Carcinoma)、治療薬(医薬品、薬剤)、製薬企業、研究開発、治験、製品パイプライン

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経内分泌がん(Neuroendocrine Carcinoma):治療薬開発パイプライン動向2014]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆